FDA Approves Ozempic for Diabetic Kidney Disease Risk Reduction
Written by: Daniel Trecroci
2 minute read
January 29, 2025
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney failure, disease progression, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD).
The FDA’s decision makes Ozempic the first GLP-1 receptor agonist approved for these kidney-related complications.
A Groundbreaking Option for Diabetes and Kidney Disease
- Ozempic’s new approval marks a significant step forward for diabetes care, as many people living with type 2 diabetes also have CKD.
- Ozempic is already recognized for managing type 2 diabetes and reducing cardiovascular risks; it is now approved to help protect the kidneys too.
- This multi-faceted approach can lead to better overall health outcomes and improved quality of life for individuals.
Empathy for Those at Risk
Silent but serious, CKD often progresses without symptoms in people with diabetes, making early treatment crucial.
Risk factors for CKD include:
- Chronically high blood pressure
- Chronically high blood sugar
- A family history of kidney problems
The FDA approval brings new hope for better outcomes for those with diabetes and kidney disease.
If you have these risk factors, it might be worth discussing this new treatment option with your doctor.
A Growing Role for GLP-1 Medications
How have you observed GLP-1 medications, such as Wegovy and Ozempic, expanding their impact beyond diabetes care?
We’d love to hear your insights on this evolving trend through our BT1 and BT2 apps.
Author
Daniel Trecroci
Dan has written about diabetes for more than 20 years. He was one of Diabetes Health's first hires. Throughout his 10+ years as Managing Editor, he wrote/published thousands of articles and helped establish Diabetes Health as the premiere resource for people with diabetes. He later became the Content Manager for OneTouchGold—Johnson & Johnson/LifeScan’s official digital publication for its metering technology customers. Under his leadership, OneTouchGold received the Web Marketing Association’s award for “Best Health & Wellness" web site. Dan has also written for the Diabetes Research Institute, dLife, diaTribe, Healthline, CareDx, Pendulum Therapeutics, and Hero Bread.
Related Resources
Managing type 2 diabetes with insulin can be challenging, but a new study shows the...
Read more
Editor’s Note: SGLT-2 inhibitors and GLP-1 receptor agonists are medicines approved by the FDA for...
Read more
You know how trying to juggle multiple things at once can leave you dropping the...
Read more